Gene Therapy is Finally Here, But Who Will Foot the Bill – Wall Street Pit
|
Gene Therapy is Finally Here, But Who Will Foot the Bill
Wall Street Pit Cancer, diabetes, and heart disease are classified as multifactorial inheritance genetic disorders. Considering all these, one would expect that the world will be welcoming the revolutionary gene therapy with wide-open arms. Yet, UniQure’s Glybera has … |
|
USC Stem Cell scientists obtain ‘how to’ guide for producing hair follicles
EurekAlert (press release) In the study, first author Mingxing Lei, a postdoctoral scholar in the USC Stem Cell laboratory of Cheng-Ming Chuong, and an international team of scientists started with dissociated skin cells from a newborn mouse. Lei then took hundreds of timelapse … |
|
REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the …
Nasdaq ROCKVILLE, Md., Aug. 11, 2017 (GLOBE NEWSWIRE) — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology … |
The Jewish Standard |
An award-winning Israeli cancer researcher talks about immunotherapy
The Jewish Standard YY: “Immunotherapy is at the very heart of my research. One clear way to void the growth factors is to use antibodies. Antibodies are molecules — we can engineer them to get rid of growth factors. Now, we can engineer the antibodies to make them … |
FierceBiotech |
RNA-targeting CRISPR could yield treatments for Huntington’s, ALS
FierceBiotech CRISPR uses the Cas9 enzyme and a “guide” RNA to snip out mutations in DNA, but until recently, it has not been used to target RNA. After using the method to track RNA in live cells last year, the UC San Diego team is now correcting mistakes in RNA … |
Philadelphia magazine |
Penn Cancer Research Called “Newest Miracle Cure”
Philadelphia magazine Back in July, the gene therapy known as CAR T, named for the chimeric antigen receptor T–cells it utilizes, was unanimously recommended for approval by an FDA advisory committee. The recommendation is as close to a predictor of approval as a treatment … |